Deals
Deal activity by volume related to AI decreased by 1% year-on-year in 2023 in the pharma industry
Credit: Bert van Dijk/Getty images.
Powered by
Analysis of the key themes driving deal activity reveals that AI accounted for 1,482 pharma deals between 2019 and 2023, worth a total value of $83.1bn, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships.
The $2.7bn acquisition by Novo Nordisk was the largest disclosed deal in 2023, while the $6bn equity offering by Takeda Pharmaceutical was the largest disclosed deal in 2022.
In volume terms, AI related deal activity decreased by 1% year-on-year in 2023 and decreased by 20% year-on-year in 2022.
Deal activity related to AI in the global pharma industry in the last five years
Top deals related to AI in the pharma industry in the last five years
Deal volume by deal type for AI related deals in the pharma industry in the last five years
Acquisition accounted for the highest number of deals in the last five years, with 607 deals, followed by Venture Financing (578 deals), Equity Offering (149 deals), Private Equity (77 deals), Asset Transaction (42), Partnership (20), Merger with 9 deals.
Top financial advisors for AI related deals by value in the pharma industry in the last five years
The top financial advisors supporting deals related to AI in the pharma industry in the last five years in terms of value were Goldman Sachs & Co, UBS Group, J.P. Morgan Securities, Evercore Group, Cowen and Company, Jefferies, SVB Securities, BofA Securities, and Morgan Stanley & Co.
Top legal advisors for AI related deals by value in the pharma industry in the last five years
The top legal advisors supporting deals related to AI in the pharma industry in the last five years in terms of value were Latham & Watkins, Clifford Chance, Hengeler Mueller Partnerschaft von Rechtsanwalten, Slaughter and May, Wachtell, Lipton, Rosen & Katz, Goodwin Procter, Cleary Gottlieb Steen & Hamilton, Wilson Sonsini Goodrich & Rosati Professional, Ropes & Gray, and Cooley.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.
